169 related articles for article (PubMed ID: 34495053)
21. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
[TBL] [Abstract][Full Text] [Related]
22. Modified American College of Radiology Thyroid Imaging Reporting and Data System and Modified Artificial Intelligence Thyroid Imaging Reporting and Data System for Thyroid Nodules: A Multicenter Retrospective Study.
Li X; Peng C; Liu Y; Hu Y; Yang L; Yu Y; Zeng H; Huang W; Li Q; Tao N; Cao L; Zhou J
Thyroid; 2024 Jan; 34(1):88-100. PubMed ID: 37950720
[No Abstract] [Full Text] [Related]
23. Differences in risk of malignancy and management recommendations in subcategories of thyroid nodules with atypia of undetermined significance or follicular lesion of undetermined significance: the role of ultrasound-guided core-needle biopsy.
Choi YJ; Baek JH; Ha EJ; Lim HK; Lee JH; Kim JK; Song DE; Shong YK; Hong SJ
Thyroid; 2014 Mar; 24(3):494-501. PubMed ID: 23947771
[TBL] [Abstract][Full Text] [Related]
24. Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital.
Al Dawish M; Alwin Robert A; Al Shehri K; Hawsawi S; Mujammami M; Al Basha IA; Alrasheed M; Asiri S; Alzouman M; Alkharashi E
Cureus; 2020 May; 12(5):e8202. PubMed ID: 32455091
[TBL] [Abstract][Full Text] [Related]
25. The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System.
Sullivan PS; Hirschowitz SL; Fung PC; Apple SK
Cancer Cytopathol; 2014 Dec; 122(12):866-72. PubMed ID: 25078420
[TBL] [Abstract][Full Text] [Related]
26. Malignancy rate of atypia of undetermined significance/follicular lesion of undetermined significance in thyroid nodules undergoing FNA in a suburban endocrinology practice: A retrospective cohort analysis.
Seagrove-Guffey MA; Hatic H; Peng H; Bates KC; Odugbesan AO
Cancer Cytopathol; 2018 Oct; 126(10):881-888. PubMed ID: 30335212
[TBL] [Abstract][Full Text] [Related]
27. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
28. Malignancy risk and characteristics of thyroid nodules with two consecutive results of atypia of undetermined significance or follicular lesion of undetermined significance on cytology.
Park VY; Kim EK; Kwak JY; Yoon JH; Moon HJ
Eur Radiol; 2015 Sep; 25(9):2601-7. PubMed ID: 25740802
[TBL] [Abstract][Full Text] [Related]
29. Risk factors associated with malignancy and with triage to surgery in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Kuru B; Atmaca A; Tarim IA; Kefeli M; Topgul K; Yoruker S; Elmali M; Danaci M
Eur J Surg Oncol; 2016 Jan; 42(1):87-93. PubMed ID: 26527545
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic Performance of Ultrasound Patterns by K-TIRADS and 2015 ATA Guidelines in Risk Stratification of Thyroid Nodules and Follicular Lesions of Undetermined Significance.
Hong HS; Lee JY
AJR Am J Roentgenol; 2019 Aug; 213(2):444-450. PubMed ID: 31039023
[No Abstract] [Full Text] [Related]
31. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology.
Na DG; Kim JH; Sung JY; Baek JH; Jung KC; Lee H; Yoo H
Thyroid; 2012 May; 22(5):468-75. PubMed ID: 22304417
[TBL] [Abstract][Full Text] [Related]
32. Reclassification of cytologically atypical thyroid nodules based on radiologic features in pediatric patients.
Arva NC; Deitch SG
J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):753-60. PubMed ID: 25879311
[TBL] [Abstract][Full Text] [Related]
33. Low Malignancy Rates in Fine-Needle Aspiration Cytologies in a Primary Care Setting in Germany.
Eszlinger M; Ullmann M; Ruschenburg I; Böhme K; Görke F; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Paschke R
Thyroid; 2017 Nov; 27(11):1385-1392. PubMed ID: 28982301
[TBL] [Abstract][Full Text] [Related]
34. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
Wu H; Zhang B; Cai G; Li J; Gu X
PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
[TBL] [Abstract][Full Text] [Related]
35. Correlation of TIRADS scoring in thyroid nodules with preoperative fine needle aspiration biopsy and postoperative specimen pathology.
Atar C; Dalcı K; Aktar Y; Totik N; Topal U; Eray İC; Akçam AT; Sakman G
Head Neck; 2024 Apr; 46(4):849-856. PubMed ID: 38197158
[TBL] [Abstract][Full Text] [Related]
36. Improving Malignancy Prediction in AUS/FLUS Pediatric Thyroid Nodules with the Aid of Ultrasound.
Arora S; Khoury J; Trout AT; Chuang J
Horm Res Paediatr; 2020; 93(4):239-244. PubMed ID: 32894855
[TBL] [Abstract][Full Text] [Related]
37. The diagnostic efficacy and inappropriate biopsy rate of ACR TI-RADS and ATA guidelines for thyroid nodules in children and adolescents.
Li G; Zhang B; Liu J; Xiong Y
Front Endocrinol (Lausanne); 2023; 14():1052945. PubMed ID: 37051202
[TBL] [Abstract][Full Text] [Related]
38. A Single-Center Retrospective Validation Study of the American College of Radiology Thyroid Imaging Reporting and Data System.
Zheng Y; Xu S; Kang H; Zhan W
Ultrasound Q; 2018 Jun; 34(2):77-83. PubMed ID: 29596298
[TBL] [Abstract][Full Text] [Related]
39. Malignancy rate associated with Bethesda category III (AUS/FLUS) with and without repeat fine needle aspiration biopsy.
Kuru B; Atmaca A; Kefeli M
Diagn Cytopathol; 2016 May; 44(5):394-8. PubMed ID: 26917413
[TBL] [Abstract][Full Text] [Related]
40. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
